Masimo (NASDAQ:MASI – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.800-4.000 for the period, compared to the consensus EPS estimate of 3.880. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion. Masimo also updated its FY24 guidance to $3.80-4.00 EPS.
Masimo Stock Up 1.3 %
NASDAQ MASI traded up $1.84 on Wednesday, reaching $142.89. The stock had a trading volume of 617,861 shares, compared to its average volume of 673,961. The business has a 50 day moving average price of $128.12 and a 200 day moving average price of $125.01. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. Masimo has a 1 year low of $75.36 and a 1 year high of $153.93. The company has a market capitalization of $7.60 billion, a price-to-earnings ratio of 95.95 and a beta of 0.99.
Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. On average, analysts forecast that Masimo will post 3.88 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Report on MASI
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Read More
- Five stocks we like better than Masimo
- What Are Growth Stocks and Investing in Them
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What Are Some of the Best Large-Cap Stocks to Buy?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- What is the Australian Securities Exchange (ASX)
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.